1. Scrip
  2. >>COVID-19

Wary Of Coronavirus Hype And Haste, Themis Looks To Future As Part Of Merck & Co.

Shared Culture Helped Seal Acquisition

 
• By Andrew McConaghie

Themis’ CEO on how Merck’s commitment to infectious diseases impressed him, and why regulators may not approve suboptimal COVID-19 vaccines.

Vienna_Conference_Center
Themis was established in Vienna in 2009

Acquired last month by Merck & Co. Inc. as it made its entry into the COVID-19 field, Austrian vaccines specialist Themis will help spearhead the big pharma company’s strategy on Sars-CoV-2, and help it build a long-term pandemic preparedness capability.

Themis’ CEO Erich Tauber is clear that the deal with the US pharma giant is a good cultural fit, telling Scrip that as both he and Merck were wary of the “hype” and haste that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

 
• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

 
• By Lisa Takagi

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.

More from Scrip